Literature DB >> 31941580

Ischemic Stroke with Protein S Deficiency Treated by Apixaban.

Ikkei Ohashi1, Shinichi Wada2, Fumitaka Yoshino3, Takahiro Kuwashiro3, Shinya Matsumoto4, Taeko Hotta4, Dongchong Kang4, Yasushi Okada3, Shun Shimohama5, Masahiro Yasaka3.   

Abstract

A 57-year-old man with atherosclerosis obliterans was admitted with sudden-onset sensory aphasia and right hemiparesis. Brain MRI revealed acute cerebral infarctions in the left temporal lobe and magnetic resonance angiography showed occlusion of the posterior branch of the left middle cerebral artery. Transesophageal echocardiography and ultrasonography respectively confirmed a patent foramen ovale and deep vein thrombosis in the bilateral femoral veins. Blood findings showed low protein S antigen, low protein S activity, and a missense mutation of the PROS 1 gene. The administration of apixaban 10 mg BID prevented ischemic stroke recurrence and decreased the deep vein thrombosis. These outcomes indicated that apixaban may be alternative to warfarin for the secondary prevention of ischemic stroke in a patient with a protein S deficiency.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Stroke; apixaban; atherosclerosis; protein S deficiency

Year:  2020        PMID: 31941580     DOI: 10.1016/j.jstrokecerebrovasdis.2019.104608

Source DB:  PubMed          Journal:  J Stroke Cerebrovasc Dis        ISSN: 1052-3057            Impact factor:   2.136


  3 in total

1.  Rivaroxaban in Recurrent Ischemic Stroke Due to Protein S Deficiency: A Case Report.

Authors:  Saba Naghavi; Ahmad Pourmohammadi; Iman Adibi
Journal:  Neurol Ther       Date:  2021-01-30

Review 2.  Protein S: function, regulation, and clinical perspectives.

Authors:  Rinku Majumder; Tina Nguyen
Journal:  Curr Opin Hematol       Date:  2021-09-01       Impact factor: 3.218

Review 3.  Recent advances in use of fresh frozen plasma, cryoprecipitate, immunoglobulins, and clotting factors for transfusion support in patients with hematologic disease.

Authors:  Prajeeda M Nair; Matthew J Rendo; Kristin M Reddoch-Cardenas; Jason K Burris; Michael A Meledeo; Andrew P Cap
Journal:  Semin Hematol       Date:  2020-07-27       Impact factor: 3.851

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.